2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2271

Does Arthritis in the Young Adult Life Phase Impact Involvement in Transitional Social Roles?

Epidemiology and Public Health Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 2518

Does the Cytokine Pattern, Including the IL23 – IL17 Immune Axis, Change in Pregnant Women with Psoriatic Arthritis?

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2206

Dopamine Pathway and Bone Metabolism in Arthritis

Biology and Pathology of Bone and Joint: Bone Remodeling and Metabolism

9:00AM-11:00AM: Abstract Number: 2777

Drug Retention Rates of Biologic Monotherapies for Patients with Rheumatoid Arthritis Receiving TNF Inhibiting Fusion Protein Agent and Antibody Agent; From Multicenter Registry in Japan

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2716

Dysregulated Osteoclastogenesis Is Related to Natural Killer T Cell Dysfunction in Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2836

Early Clinical Response Is a Better Predictor of Long-Term Remission Than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2243

Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2733

Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2668

Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2579

Effect of Tacrolimus on Endoplasmic Reticulum Stress-Mediated Osteoclastogenesis in a Collagen-Induced Arthritis Mouse Model

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2919

Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2859

Effect of Weight on Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2871

Effectiveness and Safety of Golimumab in the Treatment of Ankylosing Spondylitis over a 12 Month Period

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2866

Effectiveness and Safety of Golimumab in the Treatment of Psoriatic Arthritis over a 12 Month Period

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2753

Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].